NeuroDerm (NDRM) and The Competition Financial Contrast
NeuroDerm (NASDAQ: NDRM) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare NeuroDerm to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Insider and Institutional Ownership
52.4% of NeuroDerm shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
NeuroDerm has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, NeuroDerm’s rivals have a beta of 6.62, suggesting that their average share price is 562% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for NeuroDerm and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NeuroDerm currently has a consensus target price of $45.86, suggesting a potential upside of 18.04%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.07%. Given NeuroDerm’s rivals stronger consensus rating and higher possible upside, analysts plainly believe NeuroDerm has less favorable growth aspects than its rivals.
This table compares NeuroDerm and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares NeuroDerm and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|NeuroDerm Competitors||$260.16 million||$66.28 million||-6.36|
NeuroDerm’s rivals have higher revenue and earnings than NeuroDerm. NeuroDerm is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
NeuroDerm rivals beat NeuroDerm on 8 of the 12 factors compared.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson’s disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson’s disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson’s disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.